High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS

Figures & data

Figure 1. Plain language summary

Figure 2. Clonal complexes distribution in the 520-strain panel, by year and overall

NA, genotyping data not available; ST, sequence type; CC, clonal complex; ET, electrophoretic type; N, number of isolates.

Figure 3. 4CMenB peptides and subvariants and their distribution in the 520-strain panel

4CMenB, 4-component meningococcal serogroup B vaccine; fHbp, factor H binding protein; NHBA, neisserial heparin binding antigen; nadA, Neisseria adhesin A; PorA, porin A; VR, variable region.Notes: the labels above the bars indicate the number and percentage of strains with the same genotype feature. * Only peptides/profiles detected in ≥2% of isolates are shown.

Table 1. Strain coverage predicted by MATS and gMATS, overall and by year of sample collection, state/territory, and the patient’s age group

	N	MATS coverage, % (95% CI)	gMATS coverage, % (LL-UL)
Overall	520	74.6 (61.1–85.6)	81.0 (75.0–86.9)
By year
2007	108	70.4 (57.4–83.3)	79.2 (74.1–84.3)
2008	119	81.5 (69.7–89.0)	82.8 (76.5–89.1)
2009	103	70.9 (58.2–81.5)	80.1 (75.7–84.5)
2010	93	77.4 (60.2–87.1)	87.6 (81.7–93.5)
2011	97	72.2 (58.8–86.6)	75.3 (67.0–83.5)
By state/territory
New South Wales & ACT	156	71.8 (54.5–82.0)	78.5 (71.8–85.3)
Northern Territory	4	–*	62.5 (50.0–75.0)
Queensland	141	85.1 (73.0–94.3)	87.2 (84.4–90.1)
South Australia	40	90.0 (90.0–95.0)	93.8 (92.5–95.0)
Tasmania	9	–*	66.7 (66.7–66.7)
Victoria	118	73.7 (56.8–85.6)	80.9 (71.2–90.7)
Western Australia	52	51.9 (42.3–71.1)	65.4 (57.7–73.1)
By age group**
<1 year	75	64.0 (53.3–74.7)	68.7 (58.7–78.7)
1–<2 years	28	71.4 (64.3–89.3)	76.8 (67.9–85.7)
2–<5 years	30	83.3 (66.7–90.0)	98.3 (96.7–100)
5–29 years	118	80.5 (66.1–91.5)	86.4 (82.2–90.7)
>29 years	68	75.0 (58.8–86.8)	77.9 (72.1–83.8)

MATS, meningococcal antigen typing system; gMATS, genetic MATS; 4CMenB, 4-component meningococcal serogroup B vaccine; N, number of tested isolates; CI, coverage interval; LL, lower limit; UL, upper limit; ACT, Australian Capital Territory.

Notes: * Not calculated, due to the small number of strains isolated.

** The age of the patient from whom the sample was collected was only documented for 319 of the total 520 strains.

Figure 4. Number and percentage of MenB strains from the 520-strain panel covered in MATS, by number of 4CMenB vaccine antigens (a) and vaccine antigen/combination of antigens (b)

MenB, meningococcal serogroup B; MATS, meningococcal antigen typing system; 4CMenB, 4-component MenB vaccine; fHbp, factor H binding protein; NHBA, neisserial heparin binding antigen; NadA, Neisseria adhesin A; PorA, porin A. Note: the labels above the bars indicate the number and percentage of covered strains.

Figure 5. Number and percentage of MenB strains from the 520-strain panel covered in gMATS, by number of 4CMenB vaccine antigens (a) and vaccine antigen/combination of antigens (b)

MenB, meningococcal serogroup B; gMATS, genetic meningococcal antigen typing system; 4CMenB, 4-component MenB vaccine; NA, genotyping data not available; fHbp, factor H binding protein; NHBA, neisserial heparin binding antigen; PorA, porin A. Note: the labels above the bars indicate the number and percentage of covered strains.